Printer Friendly

BRISTOL-MEYERS SQUIBB REPORTS RESULTS

 BRISTOL-MEYERS SQUIBB REPORTS RESULTS
 NEW YORK, Jan. 16 /PRNewswire/ -- Bristol-Myers Squibb Company


(NYSE: BMY) reported record sales and earnings for the year and fourth quarter ended Dec. 31, 1991.
 For the year, sales increased 8 percent to $11.2 billion. Net earnings increased 18 percent to $2,056 million, and earnings per share increased 19 percent to $3.95 per share compared to $3.33 per share last year.
 Sales for the quarter were the highest in the company's history, increasing 7 percent to $2.9 billion. Net earnings increased 20 percent to $510 million, and earnings per share increased 21 percent to $.98 per share compared to $.81 per share last year.
 Richard L. Gelb, chairman and chief executive officer, said that for the year domestic sales increased 10 percent and international sales increased 6 percent. He added that, excluding discontinued operations, all business groups except consumer products showed sales improvement over the prior year; sales of pharmaceuticals and medical devices were strong, increasing 12 percent and 15 percent, respectively. Nutritional sales increased 9 percent, while sales of consumer products were at prior year levels. Exchange rate fluctuations had an unfavorable effect on sales of approximately 2 percent for the quarter and 1 percent for the year.
 BRISTOL-MYERS SQUIBB COMPANY
 Summary of Consolidated Sales and Earnings
 (In Thousands of Dollars Except for Per Share Amounts)
Quarter Ended 12/31/91 12/31/90 Pct.
 Increase(A)
Net Sales $2,937,220 $2,735,913 7
Earnings Before Income Taxes 703,726 607,082 16
Provision for Income Taxes 193,763 181,632 7
Net Earnings 509,963 425,450 20
Earnings Per Common Share $.98 $.81 21
Year Ended 12/31/91 12/31/90 Pct.
 Increase(A)
Net Sales $11,159,418 $10,299,729 8
Earnings Before Income Taxes 2,886,945 2,523,760 14
Provision for Income Taxes 831,440 776,057 7
Net Earnings 2,055,505 1,747,703 18
Earnings Per Common Share $3.95 $3.33 19
Average Common Shares Outstanding 520,869
 525,337 (A) -- Excluding sales of discontinued operations, sales growth was 8 percent for the quarter and 10 percent for the year.
 -0- 1/16/92
 /CONTACT: Elizabeth M. Sigler of Bristol-Myers Squibb,


212-546-5764/
 (BMY) CO: Bristol-Myers Squibb Company ST: New York IN: MTC SU: ERN SB -- NY013 -- 0344 01/16/92 08:42 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 16, 1992
Words:397
Previous Article:ROLLINS TRUCK LEASING REPORTS FIRST FISCAL QUARTER RESULTS
Next Article:COMERICA REPORTS RECORD EARNINGS FOR 1991
Topics:


Related Articles
Bristol-Myers hires project mgr.
BRISTOL-MYERS SQUIBB REPORTS RESULTS
IXSYS AND BRISTOL-MYERS SQUIBB ANNOUNCE RESEARCH AGREEMENT ON TUMOR-ASSOCIATED ANTIBODIES
NIELSEN SIGNS AGREEMENT WITH BRISTOL-MYERS SQUIBB COMPANY
FDA CLEARS TAXOL(R) (PACLITAXEL) FOR USE IN TREATMENT OF METASTATIC BREAST CANCER AFTER FIRST-LINE THERAPY FAILS
Bristol-Meyers Squibb Company Engages Topro, Inc. in Worldwide Year 2000 Project
First Call Corrects Bristol-Myers Squibb Earnings Report
Next Generation Blockbuster Drugs: Why Pharma R&D's Role is Shrinking.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters